OnBioVC NEWS:

- OnBioVC Announces Beta Launch of Service
- OnBioVC 3Q11 Trend Analysis, now available
- OnBioVC 4Q11 Trend Analysis, coming soon

SEARCH THE OnBioVC DATABASE:

04

Jan

2009

Prosensa, BV: Series B $25.0M

Posted in I - Series B, Q - 4Q08, R - INTERNATIONAL, X - Muscular Dystrophy, X - RNAi

Prosena (The Netherlands) developer of RNA-based splice modulating therapeutics closed a $25M Series B financing. Participants include GIMV, AGF Management, Abingworth Management, Life Sciences Partnersand MedSciences Capital.

Venture Capital Investors
5AM Ventures Advanced Technology Ventures Alta Partners Amgen Ventures ARCH Venture Partners Bay City Capital Bessemer Venture Partners Canaan Partners Clarus Ventures Credit Agricole Private Equity Delphi Ventures Domain Associates Edmond de Rothschild Investment Partners Flagship Ventures Forbion Capital Partners HBM Bioventures Healthcare Ventures HLM Venture Partners Interwest Partners Investor Growth Capital Kaiser Permanente Ventures Kleiner Perkins Latterell Venture Partners Lilly Ventures Mohr Davidow Ventures MPM Capital New Enterprise Associates New Leaf Venture Partners Novartis Venture Fund Novo Ventures OrbiMed Pappas Ventures Polaris Venture Partners Prospect Venture Partners Quaker BioVentures Sanderling Ventures Sofinnova Partners Sofinnova Ventures SR One SV Life Sciences Third Rock Ventures TPG Biotech TVM Capital Venrock Versant Ventures

OnBioVC Friends

FluidicMEMES
IguanaBio
EyeOnFDA
Patent Baristas
Pharma's Cutting Edge
MedTechIQ
The Antibody Blog
BioJobBlog

OnBioVC Partners